UK markets closed

Calliditas Therapeutics AB (publ) (LC8.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
9.23-0.21 (-2.23%)
At close: 03:29PM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Total revenue
1,206,888
1,206,888
802,879
229,347
874
Cost of revenue
60,463
60,463
15,201
0
0
Gross profit
1,146,425
1,146,425
787,678
229,347
874
Operating expenses
Research development
502,223
502,223
414,749
357,485
241,371
Selling general and administrative
1,060,731
1,060,731
774,659
390,233
141,724
Total operating expenses
1,555,844
1,555,844
1,186,546
747,718
383,095
Operating income or loss
-409,419
-409,419
-398,868
-518,371
-382,221
Interest expense
73,199
73,199
32,795
7,108
393
Total other income/expenses net
37,655
37,655
23,568
14,149
-54,084
Income before tax
-457,017
-457,017
-409,417
-513,373
-436,151
Income tax expense
9,168
9,168
2,851
-3,836
360
Income from continuing operations
-466,185
-466,185
-412,268
-509,537
-436,511
Net income
-466,185
-466,185
-412,268
-500,293
-433,494
Net income available to common shareholders
-466,185
-466,185
-412,268
-500,293
-433,494
Basic EPS
-8.40
-8.69
-7.78
-9.84
-9.66
Diluted EPS
-8.40
-8.69
-7.78
-9.84
-9.66
Basic average shares
53,569
53,672
53,023
50,829
44,873
Diluted average shares
53,569
53,672
53,023
50,829
44,873